The Cost-Effectiveness of First-Line Cryoablation versus First-Line Antiarrhythmic Drugs in Canadian Patients with Paroxysmal Atrial Fibrillation.

BACKGROUND

The EARLY-AF (NCT02825979), STOP AF First (NCT03118518), and Cryo-FIRST (NCT01803438), randomized controlled trials (RCTs) demonstrated that cryoballoon pulmonary vein isolation reduces atrial fibrillation (AF) recurrence compared with antiarrhythmic drugs (AADs) in patients with symptomatic paroxysmal AF (PAF). This study developed a cost-effectiveness model (CEM) of first-line cryoablation compared with first-line AADs for PAF, from a Canadian healthcare payer's perspective.

METHODS

Data from the three RCTs were analysed to estimate key CEM parameters. The model structure used a decision tree for the first 12 months and a Markov model, with a three-month cycle length, for the remaining lifetime time horizon. Costs were set at 2023 Canadian dollars, health benefits were expressed as quality-adjusted life years (QALYs), and both were discounted 3% annually. Probabilistic sensitivity analysis (PSA) considered parameter uncertainty.

RESULTS

The statistical analysis estimated that first-line cryoablation generates a 47% reduction (p<0.001) in the rate of AF recurrence, a 73% reduction in the rate of subsequent ablation (p<0.001), and a 4.3% (p=0.025) increase in health-related quality of life (HRQoL), compared with first-line AADs. The PSA indicates that an individual treated with first-line cryoablation accrues less costs (-$3,862) and more QALYs (0.19) compared with first-line AADs. Cryoablation is cost saving in 98.4% of PSA iterations and has a 99.9% probability of being cost-effective at a cost-effectiveness threshold of $50,000 per QALY gained. Cost-effectiveness results were robust to changes in key model parameters.

CONCLUSION

First-line cryoballoon ablation is cost-effective when compared with AADs for patients with symptomatic PAF.

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.